Tarceva
Roche says combination therapy with its Avastin and Tarceva gets European backing for lung cancer treatment
June 8, 2016Research and Development, Sales and Marketing European Commission, NSCL, RegulationC, Roche, Tarceva, avastin, drug trial, lung cancer
Cancer drugmaker Roche (SIX: ROG) on Wednesday said the European Commission has approved its Avastin (bevacizumab) in combination with Tarceva …
Giotrif increases lung cancer survival
May 16, 2014Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer
Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …
NHS needs to understand drug costs better, says ABPI
April 10, 2014Medical Communications, Research and Development, Sales and Marketing ABPI, AGNSS, Deepak Khanna, NICE, Stephen Whitehead, Tarceva, soliris
The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …
NICE U-turn on Roche cancer drug
April 4, 2014Medical Communications, Sales and Marketing NICE, Roche, Tarceva, U-turn
Roche’s lung cancer drug Tarceva has been given a reprieve to treat relapsed lung cancer patients in the NHS after …
Roche lung cancer drug fails
March 3, 2014Research and Development, Sales and Marketing Cancer, MetMAb, NSCLC, Roche, Tarceva, avastin
An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …
Roche: NICE guidance ‘perverse’
February 4, 2014Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva
Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …
Pfizer lung cancer drug suffers late-stage setback
January 28, 2014Research and Development, Sales and Marketing Cancer, NSCLC, Pfizer, Roche, Tarceva, dacomitinib
An experimental cancer drug developed by Pfizer has failed in two separate Phase III clinical studies. Dacomitinib is a tyrosine …
FDA approves Boehringer’s lung cancer drug
July 12, 2013Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer
Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …
Boehringer submits new lung cancer drug
September 20, 2012Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib
Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …
NICE final yes for Zytiga and Tarceva
June 27, 2012Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …
Discount sways NICE into recommending Tarceva
May 10, 2012Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer
NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease. The watchdog said …
NICE no for first line Tarceva
February 17, 2012Sales and Marketing CDF, Cancer, NICE, Roche, Tarceva
NICE no for first line Tarceva Watchdog wants more information on Roche’s drug NICE is not recommending Roche’s lung cancer …
Roche’s Lung cancer test approved for Europe
December 5, 2011Research and Development, Sales and Marketing Roche, Tarceva, lung cancer
A new test which should help to better target treatment of patients with non-small cell lung cancer (NSCLC) has received …
Tarceva approval for first-line use in EGFR lung cancer
September 1, 2011Sales and Marketing NSCLC, Roche, Tarceva
Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …
Roche cancer drug Tarceva set for first-line licence
July 25, 2011Sales and Marketing Cancer, Roche, Tarceva
Roche’s cancer drug Tarceva is on course to win a first-line indication in Europe for the first time after regulatory …
